By Adrian Wildfire, Director of Scientific and Business Strategy at hVIVO COVID-19 vaccine distribution has been operational on a global scale since December 2020 and infection rates have dropped in relation to the pace and extent of the roll-out. While COVID-19 vaccines have proven effective against the early viruses, researchers are still studying how well they protect against new, more resistant SARS-CoV-2 strains.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Adrian Wildfire
Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?
Drug Molecules Andrew Bulpin, Ph.D., Head of Process Solutions, MilliporeSigma A: Penicillin has had a significant impact on society and the pharmaceutical industry. As the first true antibiotic, it ushered in advances in therapeutic medicine. Before penicillin, there were no effective treatments for infections caused by bacteria, including cholera, tuberculosis, pneumonia, and typhoid fever.
The Pandemic Diaries
Mike Grippo, Senior Vice President, Strategy & Corporate Development at Catalent Pharma Solutions COVID-19 is one of the greatest humanitarian challenges of our lifetime. I see companies acting with great resolve and resilience, addressing the immediate challenges of COVID-19, and what it represents to their workforce, customers, partners and patients. I see “unsung” heroes – people who persevere and perform in important but less visible jobs – making a significant difference.
The Pandemic Diaries
Mike Grippo, Senior Vice President, Strategy & Corporate Development at Catalent Pharma Solutions COVID-19 is one of the greatest humanitarian challenges of our lifetime. I see companies acting with great resolve and resilience, addressing the immediate challenges of COVID-19, and what it represents to their workforce, customers, partners and patients. I see “unsung” heroes – people who persevere and perform in important but less visible jobs – making a significant difference.
Failing Safely: Why Ending Some Programmes Early May Be a Recipe for Successes Later.
It was Thomas Huxley who wrote, “The great tragedy of science [is] the slaying of a beautiful hypothesis by an ugly fact.” Pharma’s recent history is filled with examples where unexpected proofs regarding lack of efficacy have emerged to kill promising products late on in their development cycle. Late-stage candidate failure can heavily impact a company’s stock and projected earnings. One of the best-known examples in recent years is Novavax’s ResVax.
Novel flu vaccine shows efficacy against mismatched H3N2 virus
Preliminary phase 2 data from a controlled human infection trial showed that an investigational influenza vaccine being developed by FluGen was protective against a substantially mismatched influenza A(H3N2) virus, the company announced. The vaccine, M2SR, showed efficacy against an H3N2 A/Belgium challenge agent developed by SGS.
The Winning Formula
In December 2017, we celebrated the 15 most exciting drug development and manufacturing technologies in The Medicine Maker’s annual Innovation Awards. But which were truly the most groundbreaking? We asked you, our readers, to decide – and we received an overwhelming response. Here, we introduce you to some of the personalities behind your top three picks – and follow their journey from initial inspiration to commercial innovation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Adrian
Contact Adrian, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack